title: Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
abstract: CONCLUSIONS
  Androgen deprivation therapy in 80 men was associated with declines in bone mineral density (BMD), which were greatest in the first year, and in the lumbar spine compared to controls. Vitamin D use was associated with improved BMD in the lumbar spine and in the first year.
  
  
  BACKGROUND
  Decreased BMD is a common side effect of androgen deprivation therapy (ADT), leading to increased risk of fractures. Although loss of BMD appears to be greatest within the first year of starting ADT, there are few long-term studies of change in BMD, and risk factors for bone loss are not well-characterized.
  
  
  METHODS
  Men aged 50+ with nonmetastatic prostate cancer starting continuous ADT were enrolled in a prospective longitudinal study. BMD was determined by dual-energy x-ray absorptiometry at baseline and yearly for 3 years. Matched controls were men with prostate cancer not receiving ADT. Multivariable regression analysis examined predictors of BMD loss.
  
  
  RESULTS
  Eighty ADT users and 80 controls were enrolled (mean age 69 years); 52.5 % had osteopenia and 8.1 % had osteoporosis at baseline. After 1 year, in adjusted models, ADT was associated with significant losses in lumbar spine BMD compared to controls (-2.57 %, p = 0.006), with a trend towards greater declines at the total hip (p = 0.09). BMD changes in years 2 and 3 were much smaller and not statistically different from controls. Use of vitamin D but not calcium was associated with improved BMD in the lumbar spine in year 1 (+6.19 %, p < 0.001) with smaller nonsignificant increases at other sites (+0.86 % femoral neck, +0.86 % total hip, p > 0.10) primarily in the first year.
  
  
  CONCLUSIONS
  Loss of BMD associated with ADT is greatest at the lumbar spine and in the first year. Vitamin D but not calcium may be protective particularly in the first year of ADT use.
authors.affiliation: Department of Medicine, University Health Network, Room EN14-214, 200 Elizabeth Street, Toronto, M5G 2C4, Ontario, Canada, shabbir.alibhai@uhn.on.ca.
authors.forename: S M H
authors.initials: SM
authors.lastname: Alibhai
authors.forename: H Z
authors.initials: HZ
authors.lastname: Mohamedali
authors.forename: H
authors.initials: H
authors.lastname: Gulamhusein
authors.forename: A H
authors.initials: AH
authors.lastname: Panju
authors.forename: H
authors.initials: H
authors.lastname: Breunis
authors.forename: N
authors.initials: N
authors.lastname: Timilshina
authors.forename: N
authors.initials: N
authors.lastname: Fleshner
authors.forename: M D
authors.initials: MD
authors.lastname: Krahn
authors.forename: G
authors.initials: G
authors.lastname: Naglie
authors.forename: I F
authors.initials: IF
authors.lastname: Tannock
authors.forename: G
authors.initials: G
authors.lastname: Tomlinson
authors.forename: P
authors.initials: P
authors.lastname: Warde
authors.forename: S
authors.initials: S
authors.lastname: Duff Canning
authors.forename: A M
authors.initials: AM
authors.lastname: Cheung
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D005272:Femur Neck / Q000503:physiopathology; D005500:Follow-Up Studies; D006621:Hip Joint / Q000503:physiopathology; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D014807:Vitamin D / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D014807:Vitamin D; D002118:Calcium
references.citation: J Urol. 2010 Oct;184(4):1316-21
references.pmid: 20723926
references.citation: Urology. 2002 Sep;60(3 Suppl 1):7-11; discussion 11-2
references.pmid: 12231037
references.citation: J Urol. 2010 Sep;184(3):918-23
references.pmid: 20643458
references.citation: J Clin Oncol. 2010 Dec 1;28(34):5038-45
references.pmid: 21041715
references.citation: BJU Int. 2009 Sep;104(6):800-5
references.pmid: 19338564
references.citation: J Urol. 2000 Jan;163(1):181-6
references.pmid: 10604342
references.citation: Osteoporos Int. 2009 Feb;20(2):239-44
references.pmid: 18551242
references.citation: J Bone Miner Res. 1997 Sep;12(9):1463-70
references.pmid: 9286763
references.citation: BMJ. 2009 Oct 01;339:b3692
references.pmid: 19797342
references.citation: Lancet Oncol. 2012 Mar;13(3):275-84
references.pmid: 22318095
references.citation: N Engl J Med. 2009 Aug 20;361(8):745-55
references.pmid: 19671656
references.citation: Osteoporos Int. 2001;12(6):438-44
references.pmid: 11446558
references.citation: Can J Urol. 2006 Feb;13(1):2962-6
references.pmid: 16515750
references.citation: J Urol. 2002 Sep;168(3):1005-7
references.pmid: 12187209
references.citation: BJU Int. 2007 Apr;99(4):812-5; discussion 815-6
references.pmid: 17378843
references.citation: J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7
references.pmid: 16189261
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3452-8
references.pmid: 19506162
references.citation: Oncologist. 2012;17(9):1171-9
references.pmid: 22836449
references.citation: Ann Intern Med. 2011 Dec 20;155(12):827-38
references.pmid: 22184690
references.citation: BMJ. 2011 Apr 19;342:d2040
references.pmid: 21505219
references.citation: J Clin Endocrinol Metab. 2012 Jun;97(6):1802-22
references.pmid: 22675062
references.citation: Urology. 2001 Jan;57(1):127-32
references.pmid: 11164157
references.citation: Urology. 2007 Jul;70(1):122-6
references.pmid: 17656221
references.citation: N Engl J Med. 2012 Jul 5;367(1):40-9
references.pmid: 22762317
references.citation: J Natl Cancer Inst. 2005 Dec 7;97(23):1768-77
references.pmid: 16333032
references.citation: JAMA. 2005 Jul 13;294(2):238-44
references.pmid: 16014598
references.citation: J Clin Densitom. 2002 Winter;5(4):435-45
references.pmid: 12665644
references.citation: Crit Rev Oncol Hematol. 2006 Dec;60(3):201-15
references.pmid: 16860998
references.citation: Am J Clin Nutr. 2007 Dec;86(6):1780-90
references.pmid: 18065599
references.citation: World J Urol. 2011 Dec;29(6):815-9
references.pmid: 21191598
references.citation: N Engl J Med. 2005 Jan 13;352(2):154-64
references.pmid: 15647578
references.citation: Epidemiology. 1990 Jan;1(1):43-6
references.pmid: 2081237
references.citation: J Urol. 2006 May;175(5):1679-83; discussion 1683
references.pmid: 16600728
references.citation: J Clin Oncol. 2010 Dec 1;28(34):5030-7
references.pmid: 21041708